Nello Mainolfi, Kymera Therapeutics CEO
June 25, 2025 11:30 AM EDT
R&D

Kymera inks deal with Gilead as part­ner­ship with Sanofi faces a switch-up

Lei Lei Wu

News Reporter

Gilead has en­list­ed Kymera Ther­a­peu­tics to de­vel­op a com­pound that it hopes can be part of the next wave of tar­get­ed breast can­cer treat­ments. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

Bright­Gene seeks a part­ner for Zep­bound-beat­ing obe­si­ty shot

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

Bay­er's stem cell group Blue­Rock re­struc­tures pipeline, lays off staffers

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times